Unicycive Therapeutics (UNCY) Competitors $0.62 +0.01 (+1.15%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$0.61 -0.01 (-1.12%) As of 02/21/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends UNCY vs. ZYBT, LFVN, VYGR, DSGN, FDMT, LFCR, CCCC, CRDF, SLRN, and LRMRShould you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Zhengye Biotechnology (ZYBT), LifeVantage (LFVN), Voyager Therapeutics (VYGR), Design Therapeutics (DSGN), 4D Molecular Therapeutics (FDMT), Lifecore Biomedical (LFCR), C4 Therapeutics (CCCC), Cardiff Oncology (CRDF), Acelyrin (SLRN), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry. Unicycive Therapeutics vs. Zhengye Biotechnology LifeVantage Voyager Therapeutics Design Therapeutics 4D Molecular Therapeutics Lifecore Biomedical C4 Therapeutics Cardiff Oncology Acelyrin Larimar Therapeutics Zhengye Biotechnology (NASDAQ:ZYBT) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking and earnings. Does the media prefer ZYBT or UNCY? In the previous week, Unicycive Therapeutics had 1 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 1 mentions for Unicycive Therapeutics and 0 mentions for Zhengye Biotechnology. Unicycive Therapeutics' average media sentiment score of 0.96 beat Zhengye Biotechnology's score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Zhengye Biotechnology Neutral Unicycive Therapeutics Positive Is ZYBT or UNCY more profitable? Company Net Margins Return on Equity Return on Assets Zhengye BiotechnologyN/A N/A N/A Unicycive Therapeutics N/A N/A -29.88% Do analysts prefer ZYBT or UNCY? Unicycive Therapeutics has a consensus target price of $5.33, indicating a potential upside of 783.00%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do institutionals and insiders hold more shares of ZYBT or UNCY? 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 24.1% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, ZYBT or UNCY? Zhengye Biotechnology has higher earnings, but lower revenue than Unicycive Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZhengye BiotechnologyN/AN/AN/AN/AN/AUnicycive Therapeutics$680K92.20-$30.54M-$0.97-0.62 Does the MarketBeat Community believe in ZYBT or UNCY? Unicycive Therapeutics received 32 more outperform votes than Zhengye Biotechnology when rated by MarketBeat users. CompanyUnderperformOutperformZhengye BiotechnologyN/AN/AUnicycive TherapeuticsOutperform Votes3276.19% Underperform Votes1023.81% SummaryUnicycive Therapeutics beats Zhengye Biotechnology on 10 of the 11 factors compared between the two stocks. Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UNCY vs. The Competition Export to ExcelMetricUnicycive TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.03M$7.04B$5.78B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-0.646.1326.4618.82Price / Sales94.17313.78457.6880.73Price / CashN/A67.8344.0437.47Price / Book-5.616.747.634.64Net Income-$30.54M$138.11M$3.18B$245.69M7 Day Performance4.19%-2.02%-1.82%-2.63%1 Month Performance-5.63%-1.54%0.22%-2.37%1 Year Performance-62.38%-3.14%17.49%13.65% Unicycive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UNCYUnicycive Therapeutics3.0839 of 5 stars$0.62+1.1%$5.33+764.5%-62.4%$64.03M$680,000.00-0.649News CoverageZYBTZhengye BiotechnologyN/A$4.99+1.0%N/AN/A$235.38MN/A0.00278Quiet Period ExpirationGap DownLFVNLifeVantage4.1055 of 5 stars$18.56+0.7%$30.50+64.3%+139.1%$232.93M$200.16M33.14260VYGRVoyager Therapeutics4.5275 of 5 stars$4.23-3.4%$15.72+271.5%-44.8%$231.09M$250.01M5.96100Upcoming EarningsNews CoverageDSGNDesign Therapeutics1.784 of 5 stars$4.08+2.8%$7.00+71.6%+81.2%$231.01MN/A-4.8040FDMT4D Molecular Therapeutics3.1263 of 5 stars$4.88+3.4%$32.13+558.3%-82.5%$225.60M$20.72M-1.71120Analyst ForecastLFCRLifecore Biomedical2.6655 of 5 stars$6.09+2.5%$8.00+31.4%-30.1%$225.51M$128.26M-10.88690CCCCC4 Therapeutics2.7279 of 5 stars$3.18-0.6%$11.60+264.8%-58.5%$224.48M$20.76M-1.87150News CoverageCRDFCardiff Oncology2.2144 of 5 stars$4.29+3.4%$10.33+140.9%+182.7%$219.35M$490,000.00-4.5620News CoverageSLRNAcelyrin2.8672 of 5 stars$2.13+3.4%$9.60+350.7%-66.0%$213.70MN/A-0.87135News CoverageGap UpHigh Trading VolumeLRMRLarimar Therapeutics1.5721 of 5 stars$3.34+2.1%$20.13+502.5%-73.5%$213.13MN/A-2.9030 Related Companies and Tools Related Companies Zhengye Biotechnology Alternatives LifeVantage Alternatives Voyager Therapeutics Alternatives Design Therapeutics Alternatives 4D Molecular Therapeutics Alternatives Lifecore Biomedical Alternatives C4 Therapeutics Alternatives Cardiff Oncology Alternatives Acelyrin Alternatives Larimar Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:UNCY) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
